

1

2 **Structural and mechanistic insight into ribosomal ITS2 RNA processing**
3 **by nuclease-kinase machinery**

4

5 Jiyun Chen,^{1,†} Hong Chen,^{1,†} Shanshan Li,^{2,†} Xiaofeng Lin,¹ Rong Hu,¹
6 Kaiming Zhang,^{2,*} and Liang Liu^{1,*}

7

8

9

10 ¹ State Key Laboratory of Cellular Stress Biology, School of Life Sciences,
11 Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102,
12 China and ² MOE Key Laboratory for Cellular Dynamics and Division of Life
13 Sciences and Medicine, University of Science and Technology of China, Hefei
14 230027, China

15

16

17 *For correspondence: kmzhang@ustc.edu.cn (K.Z.);
18 liangliu2019@xmu.edu.cn (L.L.)

19 [†]These authors contributed equally to this work.

20

21

22 **Abstract**

23 Precursor ribosomal RNA (pre-rRNA) processing is a key step in ribosome
 24 biosynthesis and involves numerous RNases. A HEPN nuclease Las1 and a
 25 polynucleotide kinase Grc3 assemble into a tetramerase responsible for rRNA
 26 maturation. Here, we report the structures of full-length *Saccharomyces*
 27 *cerevisiae* and *Cyberlindnera jadinii* Las1-Grc3 complexes, and *Cyberlindnera*
 28 *jadinii* Las1. The Las1-Grc3 structures show that the central coiled coil domain
 29 of Las1 facilitates pre-rRNA binding and cleavage, while the Grc3 C-terminal
 30 loop motif directly binds to the HEPN active center of Las1 and regulates
 31 pre-rRNA cleavage. Structural comparison between Las1 and Las1-Grc3
 32 complex exhibits that Grc3 binding induces conformational rearrangements of
 33 catalytic residues associated with HEPN nuclease activation. Biochemical
 34 assays identify that Las1 processes pre-rRNA at the two specific sites (C2 and
 35 C2'), which greatly facilitates rRNA maturation. Our structures and specific
 36 pre-rRNA cleavage findings provide crucial insights into the mechanism and
 37 pathway of pre-rRNA processing in ribosome biosynthesis.

38 Introduction

39 Ribosomes are large molecular machines assembled from numerous proteins
40 and RNAs that are responsible for protein synthesis in cells (Anger et al., 2013;
41 Gasse, Flemming, & Hurt, 2015; Khatter, Myasnikov, Natchiar, & Klaholz,
42 2015). In eukaryotes, ribosome biosynthesis is tightly coupled to cell growth
43 and cell cycle progression and is critical for regulating normal cell size and
44 maintaining cell cycle progression (Castle et al., 2013). Ribosome biosynthesis
45 is an extremely complicated process involving about 200 assembly and
46 processing factors, which are involved in a series of continuous assembly and
47 processing reactions such as ribosome protein folding, modification, assembly,
48 and precursor rRNA (pre-rRNA) processing (Gasse et al., 2015; Lafontaine,
49 2015; Pillon, Sobhany, Borgnia, Williams, & Stanley, 2017; Wu et al., 2016).
50 Mature ribosomes in yeast *Saccharomyces cerevisiae* contain 79 proteins and
51 four RNAs (25S, 18S, 5.8S, and 5S rRNA) (Doudna & Rath, 2002; Wilson &
52 Doudna Cate, 2012; Woolford & Baserga, 2013). 5S rRNA is transcribed by
53 RNA polymerase III, whereas 25S, 18S and 5.8S rRNA are cotranscribed by
54 RNA polymerase I as a single long precursor (35S pre-rRNA) (Tomecki,
55 Sikorski, & Zakrzewska-Placzek, 2017). Except 25S, 18S and 5.8S rRNA
56 sequences, the 35S pre-rRNA also includes 5'-external transcribed spacer
57 sequence (ETS), 3'-external transcribed spacer sequence, and two internal
58 transcribed spacer sequences (ITS1 and ITS2) (Fromm et al., 2017). ITS1
59 located between 5.8S and 18S rRNA and ITS2 located between 5.8S and 25S
60 rRNA (Coleman, 2003; Cote, Greer, & Peculis, 2002). The mature rRNAs are
61 generated by a large number of endonucleases and exonucleases that remove
62 these transcribed spacers step by step through multiple efficient and correct
63 processing reactions (Granneman, Petfalski, & Tollervey, 2011). The pre-rRNA
64 processing factors synergistically produce mature rRNAs and lead to an
65 accurate and efficient assembly of mature ribosome in the nucleolus, which

66 are key to cell survival (Pillon & Stanley, 2018). Mutations in the genes that
67 encode these pre-rRNA processing factors are often lethal (Tomecki et al.,
68 2017). Although numerous evolutionarily conserved protein factors have been
69 found to be involved in the processing and modification of ribosomal RNA, the
70 detailed pathways of these factors and their specific processing mechanisms
71 are not well understood.

72 Las1 and Grc3 are highly conserved proteins and have recently been
73 identified as core enzymes involved in processing and removing ITS2 spacer,
74 which is a key step in the synthesis of 60S ribosomal subunit (Gasse et al.,
75 2015; Schillewaert, Wacheul, Lhomme, & Lafontaine, 2012). Las1 is
76 characterized as a nucleolar protein essential for ribosome biogenesis, as well
77 as cell proliferation and cell viability in *Saccharomyces cerevisiae* (Castle,
78 Cassimere, & Denicourt, 2012; Castle, Cassimere, Lee, & Denicourt, 2010;
79 Doseff & Arndt, 1995). It is important to determine the role of Las1 in rRNA
80 metabolic pathways and regulatory networks associated with ribosome
81 biogenesis and cell proliferation. Recent studies have demonstrated that Las1
82 is an endoribonuclease that contains a HEPN (higher eukaryote and
83 prokaryote nucleotide binding) domain responsible for rRNA processing (Pillon
84 et al., 2020; Pillon et al., 2017). The HEPN domain must be dimerized to form
85 an active nuclease, such as the Cas13 effectors in CRISPR immune defense
86 systems, whose catalytic site is formed by two HEPN domains involved in
87 non-specific cleavage of single-stranded RNA (Knott et al., 2017; Liu, Li, Ma, et
88 al., 2017; Liu, Li, Wang, et al., 2017; Zhang et al., 2018). Interestingly, Las1
89 specifically cleaves at the C2 site within ITS2 and generates the 7S pre-rRNA
90 and 26S pre-rRNA (Fernandez-Pevida, Kressler, & de la Cruz, 2015). It is not
91 clear why Las1 HEPN nuclease specifically targets and cleaves ITS2 only at
92 C2 site, and whether this cleavage depends on a specific sequence or
93 secondary structure. In addition, the cleavage activity of Las1 is primarily

94 dependent on another enzyme Grc3. Grc3 is a polynucleotide kinase
 95 responsible not only for Las1 nuclease activation, but also for nonspecific
 96 phosphorylation of the 5'-OH of the 26S pre-rRNA produced by Las1 cleavage,
 97 providing a signal for further processing by Rat1-Rai1 exonuclease (Gordon,
 98 Pillon, & Stanley, 2019; Xiang et al., 2009). Although Cryo-EM reveals
 99 cross-linked *Chaetomium thermophilum* Las1 and Grc3 assemble into a
 100 super-dimer, due to flexibility, critical structural information is missing for the
 101 coiled coil (CC) domain of Las1 and the N-terminal and C-terminal regions of
 102 Grc3 (Pillon et al., 2019). It remains unknown how Las1 and Grc3 coordinate
 103 with each other in terms of substrate binding and nuclease activation.

104 In this study, we identified that *S. cerevisiae* (Sc) Las1 endoribonuclease
 105 initially cleaves ITS2 in a step-by-step fashion at two specific sites, which
 106 greatly promotes the maturation of 25S rRNA. Additionally, we solved the
 107 crystal structures of full-length ScLas1-Grc3 complex and *Cyberlindnera jadinii*
 108 (Cj) Las1-Grc3 complex, as well as the high resolution structure of CjLas1
 109 HEPN domain. Our structural and biochemical findings uncovered a detailed
 110 mechanism of polynucleotide kinase-mediated activation of HEPN nuclease,
 111 providing a molecular basis for clearly understanding the process of pre-rRNA
 112 processing and maturation in ribosome biosynthesis.

113 **Results**

114 **Las1 cleaves ITS2 at two specific sites**

115 HEPN endoribonucleases such as Cas13, Ire1, and RNase L are
 116 metal-independent RNA specific enzymes that efficiently cleave substrate RNA
 117 at multiple sites (Abudayyeh et al., 2016; Huang et al., 2014; Korennykh et al.,
 118 2009; Lee et al., 2008; Wang et al., 2014). Las1 is also identified as a
 119 HEPN-containing RNase, but it has only been found to initially cut ITS2 RNA at
 120 a single specific position (C2). To investigate whether there are other potential

121 sites for Las1 cleavage in ITS2, we performed *in vitro* RNA cleavage assays
 122 using a 5'-Cy5- and 3'-Cy3-labeled 33-nt ITS2 RNA substrate (Figure 1A).
 123 Las1 shows weak or no detectable activity to ITS2 in the absence of Grc3, but
 124 exhibits robust activity in the presence of Grc3 (Figure 1B, Figure 1-figure
 125 supplement 1), revealing Grc3-dependent Las1 nuclease activation.
 126 Interesting, we observed a single 5'-Cy5-labeled cleavage product, and two
 127 prominent 3'-Cy3-labeled cleavage products including a final product and an
 128 intermediate product (Figure 1B), suggesting that cleavage of ITS2 substrate
 129 occurs at two specific sites. The 33-nt ITS2 substrate RNA harbors the C2 site,
 130 which is located between nucleotides A140 and G141 (Figure 1A). In addition
 131 to the C2 site, there is another specific position in ITS2 that is able to be
 132 processed by Las1. ScLas1 cleaves the 33-nt ITS2 at C2 site to theoretically
 133 generate a 10-nt 5'-terminal product and a 23-nt 3'-terminal product (Figure
 134 1A). Our merger data shows that the final 5'-terminal and 3'-terminal product
 135 bands are at nearly the same horizontal position on the gel (Figure 1B),
 136 indicating that they are similar in size. Therefore, we hypothesize that the 23-nt
 137 3'-terminal product is an intermediate that can be further processed by Las1 at
 138 a specific site to produce two small products. We then mapped the cleavage
 139 products using the 33-nt ITS2 RNA without 5'-Cy5- and 3'-Cy3-label. We
 140 observed four cleavage bands of approximately 23-nt (P2), 14-nt (P3), 10-nt
 141 (P1), and 9-nt (P4) in length (Figure 1C). The 23-nt product (P2) is obviously
 142 an intermediate cleavage product, which is further cleaved to generate 14-nt
 143 and 9-nt products. Based on these observations, we identify that another
 144 cleavage site, which we designated as C2', is located between nucleotides
 145 G154 and C155. Las1 is able to process ITS2 at C2 and C2' sites in a
 146 step-by-step manner, resulting in a 9-nt 3'-end product and a 10-nt 5'-end
 147 product.

148 We obtained similar cleavage results with a longer 81-nt ITS2 RNA substrate

(Figure 1D, E). To further confirm the cleavage site of C2', we then mapped the cleavage sites of the 81-nt ITS2 using reverse transcription coupling sequencing methods (Figure 1F). We used an adaptor RNA to separately link the product RNA fragments to form template RNAs. After reverse transcription and sequencing of these template RNAs, we obtained the accurate sequence information for products P2 and P4, revealing that the C2 site is located between nucleotides A140 and G141, and the C2' site is located between nucleotides G154 and C155.

The cleavage products P2, P3, and P4 are all phosphorylated by Grc3, as they all show a slight shift when in the presence of ATP in the reaction (Figure 1G). This indicates that Las1 generates 5'-OH terminus following both C2 and C2' cleavage. The phosphorylated products are further degraded by Rat1-Rai1 exonuclease, especially P1 and P2, which are completely degraded under given experimental conditions (Figure 1H).

In addition, Grc3 shows no cleavage activity to ITS2 (Figure 1-figure supplement 2), and mutations in the HEPN catalytic residues of Las1 abolish C2 and C2' cleavage (Figure 1-figure supplement 3), further confirming that both C2 and C2' cleavages are attributed to metal-independent Las1 RNase (Figure 1-figure supplement 4).

Overall structures of ScLas1-Grc3 complex and CjLas1-Grc3 complex

To elucidate how Las1 and Grc3 cooperate to direct ITS2 cleavage and phosphorylation, we determined the cryo-electron microscopy (cryo-EM) and crystal structures of full-length ScLas1-Grc3 complex at 3.07 Å and 3.69 Å resolution (Figure 2, Figure 2-figure supplement 1, Table 1 and Table 2), respectively. Cleavage assay indicates that ScGrc3 can activate ScLas1 nuclease well for ITS2 cleavage, while CjGrc3 exhibits relatively weak

175 activation ability for CjLas1 nuclease (Figure 1B, Figure 1–figure supplement
176 1). To better understand the differences in the mechanisms of Grc3 activation
177 of Las1 between different species, we also solved the cryo-EM and crystal
178 structures of full-length CjLas1-Grc3 complex at 3.39 Å and 3.39 Å resolution
179 (Figure 3, Figure 3–figure supplement 1, Table 1 and Table 2), respectively. To
180 be noted, the crystal structures were solved by molecular replacement method
181 with the cryo-EM maps of Las1-Grc3 complexes. Since the crystal structures
182 have similar quality and resolve more structural information than the cryo-EM
183 structures (Figure 3–figure supplement 2), the subsequent presentations and
184 descriptions are based on the crystal structures.

185 Both structures reveal that Las1 and Grc3 assemble into a tetramer with two
186 copies of each (Figure 2B, C and Figure 3B, C). The architecture of Las1-Grc3
187 tetramer complex resembles a butterfly with outstretched wings. Las1 consists
188 of a relatively conserved N-terminal HEPN domain, a poorly conserved central
189 coiled coil (CC) domain, and a short C-terminal tail motif (LCT) (Figure 2A,
190 Figure 3A, Figure 3–figure supplement 3). Grc3 is composed of an N-terminal
191 domain (NTD), a central polynucleotide kinase (PNK) domain, a C-terminal
192 domain (CTD), and a short C-terminal loop motif (GCT). Two HEPN domains
193 from two Las1 copies are tightly symmetrically stacked together to form a
194 HEPN dimer that constructs the body of the butterfly (Figure 2B and Figure 3B).
195 Two CC domains of Las1 and two Grc3 copies assemble into the left and right
196 wings. The NTD and PNK domains of Grc3 constitute the forewing, while the
197 CTD domain of Grc3 and the CC domain of Las1 form the hindwing. All
198 domains are perfectly stacked together to build a compact and stable tetramer
199 architecture (Figure 2C and Figure 3C). Two Grc3 molecules are assembled
200 on both sides of Las1 HEPN domains to stabilize the conformation of HEPN
201 dimer. The CC domain is located on one side of Grc3 and forms a
202 sandwich-shaped structure with the Grc3 and HEPN domains (Figure 2B and

Figure 3B), resulting in Grc3 being anchored by the CC and HEPN domains. In addition, the CTD of Grc3 and the HEPN domain of Las1 tightly grasp Las1 LCT and Grc3 GCT, respectively, making Las1-Grc3 tetramer assembly more stable.

Las1 CC domain contributes to ITS2 binding and enhances cutting

In order to explore whether there are structural differences between ScLas1-Grc3 and CjLas1-Grc3 complexes, we conducted structural comparison by superposition the structures of the two complexes. Structural superposition shows that the conformations of all Grc3 domains and Las1 HEPN domains are almost identical in the two complexes, while the conformations of Las1 CC domains are significantly different (Figure 4A).

Dali server reveals that CC domain shares little structural similarity with any known proteins (Holm & Rosenstrom, 2010). CC domain is mainly composed of α helices and is the largest domain of Las1 (Figure 4B), with low sequence similarity among different species (Figure 3—figure supplement 3), yet its function remains unknown. To determine whether it plays a role in Las1 catalyzing ITS2 cleavage, we performed EMSA and *in vitro* RNA cleavage assays using Las1 proteins with or without CC domain truncations. Our data shows that the CC domain contributes to the binding of ITS2 RNA and then facilitates ITS2 cleavage (Figure 4C, D), suggesting that the CC domain may play a role of ITS2 stabilization in the Las1 cutting reaction.

Grc3 GCT binds to the HEPN active center and mediates Las1 activation

The ScLas1-Grc3 tetramer structure shows that two Grc3 GCT are stabilized by two HEPN domains of Las1 (Figure 2). Each Grc3 GCT binds to a groove in each Las1 HEPN domain and extends to the ribonuclease active center (Figure 5A), which is formed by the two HEPN domains via dimerization. The

229 conserved catalytic residues Arg129, His130, His134 with two copies from two
 230 HEPN domains form a symmetric catalytic active pocket (Figure 5B). The two
 231 C-terminals of Grc3 GCTs tightly bind to the catalytic active pocket through
 232 packing and hydrogen bond interactions. Specifically, the side chain of Trp617
 233 within Grc3 GCT inserts into the active pocket and forms packing and
 234 hydrogen bond with catalytic residue Arg129 (Figure 5B). Moreover, Trp617
 235 and His615 in Grc3 form extensive hydrogen bond with residues Arg136,
 236 Leu99, Gly98 and His54 within Las1. The Trp617 residue is highly conserved
 237 in Grc3 (Figure 5C), and its mutation completely abolishes the ITS2 cleavage
 238 (Figure 5D), but has little effect on Las1 binding (Figure 5E), revealing that it
 239 plays a crucial role in the activation of HEPN endonuclease. We also mutated
 240 each of the residues at the C-terminal of Grc3 and examined the nuclease
 241 activity of Las1 complexes with these mutants. Our data shows that alanine
 242 substitution of multiply conserved residues dramatically reduces the ITS2
 243 cleavage (Figure 5F, Figure 5—figure supplement 1), indicating that these
 244 residues are also essential for coordinating Las1 HEPN endonuclease
 245 activation.

246 **Las1 LCT drives Las1-Grc3 complex assembly**

247 Our structure exhibits that the Las1 LCT is located in a groove in the CTD
 248 domain of Grc3 (Figure 6A). Structure analysis reveals that the Las1 LCT is
 249 stabilized by the Grc3 CTD through extensive hydrophobic interactions and
 250 hydrogen bonding. The side chains of Trp488, Trp494 and Phe499 of Las1
 251 LCT are inserted into the three hydrophobic core regions of Grc3 CTD and
 252 form stable hydrophobic interactions with multitudinous hydrophobic residues
 253 of Grc3 (Figure 6B, C). Additionally, the side chain of Asn487 and the main
 254 chains of Lys497 and Ser489 of Las1 LCT form multiple hydrogen bonds with
 255 the sides of Trp573, His543 and the main side of Gln468 of Grc3 (Figure 6B,
 256 C). Mutations and deletions of Las1 LCT reduce the enzyme activity of Las1

(Figure 6—figure supplement 1). LCT deletions also significantly affect the association between Las1 and Grc3 (Figure 6—figure supplement 2). These results highlight the functional significance of the sequence-dependent recognition of Las1 LCT by Grc3 CTD.

Special crystal structure of Las1 HEPN domain

The biochemical data shows that Las1 exhibits very weak ability to cut ITS2 RNA at both C2 and C2' sites in the absence of Grc3 (Figure 1B, Figure 1—figure supplement 1), suggesting that Las1 may exist in a low-activity conformation state prior to assembly with Grc3 (Pillon et al., 2017). To determine the structure of Las1 in the low-activity conformation, we screened a lot of crystallization conditions with full-length Las1 proteins. Unfortunately, we did not obtain any crystals. We conjectured that the CC domain of Las1 might have a flexible conformation in the absence of Grc3, and then attempted to crystallize Las1 truncated by the CC domain and LCT. After screening a large number of crystallization conditions, we successfully obtained well-ordered crystals of the CjLas1 HEPN domain and determined its structure at 1.80 Å resolution using molecular replacement method (Figure 7A and Table 1).

The crystallographic asymmetric unit contained three Las1 HEPN molecules (HEPN1, HEPN2 and HEPN3), each of which assumes an all α -helical fold (Figure 7A). Analysis of crystal packing and interactions across HEPN-HEPN interfaces suggests that the biological unit of Las1 HEPN domain may contain a homodimer and a monomer. HEPN1 and HEPN2 molecules form a face to face dimer related through the pseudo-2-fold axis, similar to the HEPN dimer in the Las1-Grc3 tetramer structure. Most notably, the molecule HEPN3 is likely not to form a dimer similar to HEPN1-HEPN2 with its symmetry-related molecule. Firstly, the structural superposition of HEPN3 and its symmetry-related molecule with the HEPN1-HEPN2 dimer shows that HEPN1

284 and HEPN3 molecules superimpose well with core root mean-square deviation
285 (RMSD) of 0.7 Å for 133 Cα atoms, while HEPN2 and symmetry-related
286 HEPN3 molecule exhibit significantly different conformations (Figure 7—figure
287 supplement 1). Secondly, the catalytic residues in HEPN1 and HEPN2
288 domains are close to each other to form a compact active center, whereas the
289 catalytic residues in HEPN3 and its symmetry-related molecule remain far
290 apart, presenting two separate catalytic sites (Figure 7B, C). These
291 observations suggest that the HEPN3 molecule in the asymmetric unit is
292 probably to be a monomer, which forms a special packing with the dimer of
293 HEPN1-HEPN2 in the crystal.

294 Together, these results indicate a monomer-dimer equilibrium in the Las1
295 HEPN domain, which is consistent with the previously reported SEC-MALS
296 data (Pillon et al., 2017).

297 **Conformational changes in Las1 HEPN domain upon Grc3 binding**

298 Since Grc3 binding significantly activates the endonuclease activity of Las1,
299 the HEPN nuclease domains are probably to undergo conformational changes
300 before and after Grc3 binding. We compared the HEPN domain dimer
301 structures in CjLas1 and CjLas1-Grc3 complex by superposition and observed
302 that significant conformational changes occur in HEPN domains upon Grc3
303 binding (Figure 7D). One HEPN domain is well aligned between the two
304 structures, while the other HEPN domain has a large displacement. In order to
305 investigate whether conformational changes occurred in the catalytic center,
306 we further compared the catalytic pocket within the HEPN domains of the two
307 structures. Remarkably, Large conformational changes are observed in the
308 catalytic pocket (Figure 7D). In the Grc3-free Las1 structure, the catalytic
309 residues Arg129, His130 and His134 within one HEPN domain are far from the
310 catalytic residues in the other HEPN domain, while in the Grc3-bound structure,

the catalytic residues within two HEPN domains are close to each other (Figure 7D, Figure 7—figure supplement 2). These observations indicate that the Grc3 binding not only stabilizes the Las1 HEPN dimer, but also promotes the formation of a more compact catalytic pocket, showing better catalytic activity for specific cleavage of ITS2. Notably, compared with CjGrc3-bound CjLas1, ScGrc3-bound ScLas1 has a more compact catalytic pocket (Figure 7D, Figure 7—figure supplement 2), which may explain why ScLas1 shows better ITS2 cleavage activity than CjLas1 in the presence of Grc3 (Figure 1B, Figure 1—figure supplement 1).

Discussion

Removal of the ITS2 is the requirement for the maturation of 5.8S rRNA and 25S rRNA, which is an important step during the eukaryotic 60S subunit synthesis. In this study, the structural, biochemical, and functional analysis of ITS2 RNA processing machinery provides a critical step toward understanding the molecular mechanism of Grc3-activated ITS2 processing by Las1 endoribonuclease.

Mechanism of ITS2 processing by Las1-Grc3 dual enzyme complex

Based on our findings, we propose a model of ITS2 processing by Las1 endoribonuclease and its activator Grc3 kinase (Figure 8). In the absence of Grc3, Las1 has very weak ITS2 cleavage activity due to its unstable HEPN dimer. However, in the presence of Grc3, two copies of Las1 and Grc3 assemble into a stable tetramer that shows high activity to cleavage ITS2. Las1 initially processes ITS2 at the C2 site, generating a 5.8S rRNA precursor with 2',3'-cyclic phosphate and a 25S rRNA precursor with 5'-hydroxyl end (Figure 8 and Figure 1I). The second step of ITS2 specific cleavage occurs at the C2' site to remove the 5'-region of the 25S rRNA precursor. The C2'

337 cleavage also produces a 5'-hydroxyl product, which is rapidly phosphorylated
338 by Grc3 only in the presence of ATP. After phosphorylation, the 25S precursor
339 is further processed by a Rat1-Rai1 complex with 5'-3' exonuclease activity,
340 which degrades the 5'-region of the 25S rRNA precursor and subsequently
341 generate mature 25S rRNA (Figure 1I) (Gasse et al., 2015). Furthermore, the
342 nuclear exosome complex drives the maturation of the 5.8S RNA by removing
343 the 3'-end of the precursor through its 3'-5' exonuclease activity (Fromm et al.,
344 2017).

345 **Distinct activation mechanism for Las1 HEPN nuclease**

346 Structural and biochemical results highlight the mechanism of Grc3
347 GCT-mediated Las1 HEPN nuclease activation, which is quite distinct from
348 other HEPN nucleases such as CRISPR-Cas and toxin-antitoxin associated
349 HEPN RNases, Cas13a, Csm6, RnIA. Though proper dimerization of the
350 HEPN domain is critical for HEPN nuclease activity, other factors are also
351 common requirements for HEPN activation. For examples, activation of the
352 Cas13a HEPN enzyme requires target RNA binding and guide-target RNA
353 duplex formation, while allosterically activation of the Csm6 HEPN nuclease is
354 dependent on a cyclic oligoadenylate (Liu, Li, Ma, et al., 2017; Niewoehner et
355 al., 2017). In addition, stimulating the toxicity of RnIA HEPN RNase requires an
356 association between RnIA and RNase HI, and triggering activation of the HEPN
357 domains of Ire1 and RNase L needs binding of ATP to their kinase domains
358 (Lee et al., 2008; Naka, Koga, Yonesaki, & Otsuka, 2014; Wang et al., 2014). It
359 is noteworthy that these activators do not interact directly with the HEPN
360 domain, but bind to other domains to induce a conformational transition of the
361 HEPN domain from inactive to active state. In contrast, Grc3 GCTs bind
362 directly to the active center of HEPN domains and form hydrogen bonds with
363 catalytic residues, which appears to provoke rearrangements of the active site
364 required for activation of HEPN. Regulation of HEPN RNases by interacting

365 with catalytic residues may be a direct and effective measure.

366 **Comparison of Las1-Grc3 complex and other nuclease-kinase machines**

367 Ire1 and RNase L are also nuclease-kinase machines that contain a HEPN
 368 domain and a protein kinase domain or a pseudo-protein kinase domain,
 369 playing a fundamental role in RNA degradation related to a variety of cellular
 370 processes. Although Ire1 and RNase L also require higher-order assembly
 371 during RNA degradation, the Las1-Grc3 complex shows distinct structure
 372 assembly with them (Figure 8—figure supplement 1). Both the kinase domain
 373 and the HEPN domain in Ire1 and RNase L adopt a parallel back to back dimer
 374 configuration (Lee et al., 2008; Wang et al., 2014). In Las1, only the HEPN
 375 domain forms a dimer architecture, and Grc3 does not contact each other, but
 376 binds on both sides to stabilize the HEPN dimer. An ankyrin repeat domain in
 377 RNase L and an endoplasmic reticulum (ER) luminal domain in Ire1 has been
 378 proposed to promote dimerization of the kinase and HEPN domains (Credle,
 379 Finer-Moore, Papa, Stroud, & Walter, 2005; Huang et al., 2014). Whereas the
 380 additional CC domain in Las1 is likely to contribute to RNA binding and
 381 facilitate cleavage (Figure 4C, D). In addition, Las1, Ire1, and RNase L
 382 recognize similar RNA cleavage motifs despite being involved in different RNA
 383 processing, splicing, and degradation pathways. Cleavage studies show a
 384 preference of Las1 for UAG and UGC motifs, which are also the universal
 385 cleavage motifs observed in mRNA decay by Ire1 and RNase L (Pillon &
 386 Stanley, 2018).

387

388 **Materials and methods**

389 **Protein expression and purification**

390 For Las1-Grc3 complex expression and purification, *Saccharomyces*

391 *cerevisiae Las1* (*ScLas1*) gene was cloned into pET23a vector with an
392 N-terminal His₆-tag and *Cyberlindnera jadinii* (*CjLas1*) gene was cloned into
393 pET28a vector with an N-terminal His₆SUMO-tag, while *ScGrc3* and *CjGrc3*
394 genes were cloned into modified pET28a vector containing an N-terminal
395 SUMO-tag, followed by an ubiquitin-like protein1 (Ulp1) protease cleavage site.
396 All recombinant plasmids were transformed into *E.coli* Rosetta (DE3)
397 (Novagen) cells and grown in LB broth at 37°C for 3 h. After culturing to an
398 OD₆₀₀ of 0.6-0.8, protein expression was induced with 0.2 mM
399 isopropyl-1-thio-β-D-galactopyranoside (IPTG) at 16°C for 14 h. For the
400 purification of *ScLas1*-Grc3 complex proteins, cells expressing *ScLas1*
401 proteins and *ScGrc3* proteins were collected and co-lysed by sonication in
402 buffer containing 20 mM Tris-HCl, pH 7.5, 500 mM NaCl. After centrifugation,
403 supernatant was incubated with Ni Sepharose (GE Healthcare), and the bound
404 protein was eluted with buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM
405 NaCl, 300 mM imidazole. Eluted protein was digested with Ulp1 protease at
406 4°C for 2 h and then further purified on a Heparin HP column (GE Healthcare),
407 eluting with a linear gradient of increasing NaCl concentration from 300 mM to
408 1 M in 20 mM Tris-HCl, pH7.5 buffer. The fractions containing the protein of
409 interest were concentrated and further purified by size-exclusion
410 chromatography (Superdex 200 Increase 10/300, GE Healthcare) in a buffer
411 containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, and 1 mM
412 Tris(2-carboxyethyl)phosphine hydrochloride (TCEP). Proteins were collected
413 and concentrated to a final concentration of 15 mg/ml. For the purification of
414 *CjLas1*-Grc3 complex proteins, cells expressing *CjLas1* proteins and *CjGrc3*
415 proteins were collected and co-lysed by sonication in buffer containing 20 mM
416 Tris-HCl, pH 7.5, 500 mM NaCl. After centrifugation, supernatant was
417 incubated with Ni Sepharose (GE Healthcare), and the bound protein was
418 eluted with buffer containing 20 mM Tris-HCl, pH 7.5, 350 mM NaCl, 300 mM
419 imidazole. Eluted protein was digested with Ulp1 protease at 4°C for 2 h and

then further purified on a Heparin HP column (GE Healthcare), eluting with buffer containing 20 mM Tris-HCl, pH7.5, 1M NaCl. The protein was further purified by size-exclusion chromatography (Superdex 200 Increase 10/300, GE Healthcare) in a buffer containing 20 mM Tris-HCl, pH 7.5, 350 mM NaCl, and 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP). Proteins were collected and concentrated to a final concentration of 15 mg/ml. Mutants were expressed and purified as wild-type protein. The CjLas1 HEPN construct was purified with an identical protocol.

For the experiment of GST pull-down, the wild-type *ScLas1* gene and its mutants were cloned into a modified pET23a vector (Novagen) with an N-terminal His₆GST-tag, while the wild-type *ScGrc3* gene and its mutants were cloned into a modified pET28a vector containing an N-terminal His₆SUMO-tag. Proteins were overexpressed in *E.coli* Rosetta (DE3) (Novagen) cells and cultured in LB broth to an OD₆₀₀ of 0.6-0.8. Then the target proteins were induced with 0.2 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and grown for additional 14 h at 16°C. Cells were collected and lysed by sonication in buffer containing 20 mM Tris-HCl, pH 7.5, 500 mM NaCl. After centrifugation, supernatant was incubated with Ni Sepharose (GE Healthcare), and the bound protein was eluted with buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 300 mM imidazole. The GST-ScLas1 mutants were further purified on a Heparin HP column (GE Healthcare) and ScGrc3 mutants were purified on a HitTrap Q HP column (GE Healthcare). All proteins were further purified by size-exclusion chromatography (Superdex 200 Increase 10/300, GE Healthcare) in a buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl.

Crystallization, data collection and structure determination

Crystals of ScLas1-Grc3 complex, CjLas1-Grc3 complex and CjLas1 truncated protein (HEPN domain) were first obtained using the sitting drop vapor diffusion method using high-throughput crystallization screening kits (Hampton

Research, Molecular Dimensions and QIAGEN). Crystals were then grown in a mixed solution containing 1 μ l complex solution and 1 μ l of reservoir solution using the hanging drop vapor diffusion method at 16°C. For growing large crystals, crystals were further optimized by using seeding technique. Well-diffracting crystals of ScLas1-Grc3 complex were grown in a reservoir solution containing 2% (v/v) tacsimate, pH 7.0, 0.1 M imidazole, pH 7.0, 2% (v/v) 2-propanol, and 9% (w/v) PEG 3350. Well-diffracting crystals of CjLas1-Grc3 complex were grown in a reservoir solution containing 0.1 M sodium phosphate, pH 7.5, 0.05 M NaCl, and 9% (w/v) PEG 4000. The best crystals of CjLas1 HEPN domain protein were grown from 0.1 M Tris-HCl, pH 8.0, 0.2 M MgCl₂, and 25% (w/v) PEG 3350. All crystals soaked in cryoprotectants made from the mother liquors supplemented with 20% (v/v) glycerol and flash frozen in liquid nitrogen.

All diffraction data sets were collected at beamline BL-17U1, BL-18U1, and BL-19U1 at Shanghai Synchrotron Radiation Facility (SSRF) and National Center for Protein Sciences Shanghai (NCPSS), and processed with HKL3000 (Otwinowski & Minor, 1997). The CjLas1 HEPN structure were determined by molecular replacement using the HEPN domain structure within CtLas1-Grc3 (PDB: 6OF4) as the search model using the program PHENIX Phaser (Adams et al., 2002; Pilon et al., 2019). The phases of ScLas1-Grc3 complex and CjLas1-Grc3 complex were solved by molecular replacement method with the cryo-EM maps of Las1-Grc3 complexes using PHENIX Phaser. The model was manually built and adjusted using the program COOT (Emsley, Lohkamp, Scott, & Cowtan, 2010). Iterative cycles of crystallographic refinement were performed using PHENIX. All data processing and structure refinement statistics are summarized in Supplementary Table 1. Structure figures were prepared using PyMOL (<http://www.pymol.org/>).

Cryo-EM data acquisition

476 The samples were diluted at a final concentration of around 1.0 mg/mL. Three
477 microliters of the samples were applied onto glow-discharged 200-mesh R2/1
478 Quantifoil copper grids. The grids were blotted for 4 s and rapidly cryocooled in
479 liquid ethane using a Vitrobot Mark IV (Thermo Fisher Scientific) at 4°C and
480 100% humidity. The samples were imaged in a Titan Krios cryo-electron
481 microscope (Thermo Fisher Scientific) at a magnification of 105,000×
482 (corresponding to a calibrated sampling of 0.82 Å per pixel). Micrographs were
483 recorded by EPU software (Thermo Fisher Scientific) with a K3 detector, where
484 each image was composed of 30 individual frames an exposure time of 3 s
485 and an exposure rate of 16.7 electrons per second per Å². A total of 2,520
486 movie stacks for ScLas1-Grc3 complex and 8,616 movie stacks for
487 CjLas1-Grc3 complex were collected.

488 **Single-particle image processing and 3D reconstruction**

489 All micrographs were first imported into Relion (Scheres, 2012) for image
490 processing. The motion-correction was performed using MotionCor2 (Zheng et
491 al., 2017) and the contrast transfer function (CTF) was determined using
492 CTFFIND4 (Rohou & Grigorieff, 2015). All particles were autopicked using the
493 NeuralNet option in EMAN2 (Tang et al., 2007). Then, particle coordinates
494 were imported to Relion, where the poor 2D class averages were removed by
495 several rounds of 2D classification. Initial maps were built and classified using
496 ab-initio 3D reconstruction in cryoSPARC (Punjani, Rubinstein, Fleet, &
497 Brubaker, 2017) without any symmetry applied. Heterogeneous refinement
498 was further performed to remove bad particles using one good and one bad
499 starting maps. The good class having 264,341 particles for ScLas1-Grc3
500 complex or 523,843 particles for CjLas1-Grc3 complex was selected and
501 subjected to 3D homogeneous refinement, local & global CTF refinement, and
502 non-uniform refinement with C2 symmetry imposed, achieving a 3.07 Å
503 resolution map for the ScLas1-Grc3 complex and a 3.39 Å resolution map for
504 the CjLas1-Grc3 complex, respectively. Resolution for the final maps were

505 estimated with the 0.143 criterion of the Fourier shell correlation curve.
506 Resolution maps were calculated in cryoSPARC using the “Local Resolution
507 Estimation” option. (More information in Supplementary Figure S2,
508 Supplementary Figure S3, and Supplementary Table 2).

509 ***In vitro* transcription of RNA**

510 Unlabeled ITS2 RNAs used for cleavage assays were synthesized by *in vitro*
511 transcription with T7 RNA polymerase and linearized plasmid DNAs as
512 templates. Transcription reactions were performed at 37°C for 4 h in buffer
513 containing 100 mM HEPES-KOH, pH 7.9, 20 mM MgCl₂, 30 mM DTT, 2 mM
514 each NTP, 2 mM spermidine, 0.1 mg/ml T7 RNA polymerase, and 40 ng/μl
515 linearized plasmid DNA template. The transcribed RNA was then purified by
516 gel electrophoresis on a 12% denaturing (8 M urea) polyacrylamide gel, RNA
517 band was excised from the gel and recovered with Elutrap System. The
518 purified RNA was resuspended in DEPC (diethyl pyrocarbonate)-treated water.

519 ***In vitro* ITS2 RNA cleavage assays**

520 For 5'-Cy5 and 3'-Cy3 labeled ITS2 RNA cleavage assays, 0.5 μM of ITS2
521 RNA was incubated at 37°C for 2 h with increasing amount of Las1, Grc3 or
522 Las1-Grc3 complex proteins (0.05 μM-0.5 μM) in cleavage buffer containing 20
523 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine
524 hydrochloride (TCEP). 5'-Cy5 and 3'-Cy3 labeled ITS2 RNA was synthesized
525 from Takara Biomedical Technology. Reactions were stopped by adding 2 ×
526 loading buffer. Samples were analyzed on a 20% urea denaturing
527 polyacrylamide gel with TBE buffer. Cleavage products were visualized by
528 fluorescent imaging and analysis system (SINSAGE TECHNOLOGY).

529 For unlabeled ITS2 RNA cleavage assays, 10 μM of ITS2 RNA was
530 incubated at 37°C for 2 h with increasing amount of Las1, Grc3 or Las1-Grc3
531 complex proteins (1.5 μM-15 μM) in cleavage buffer containing 20 mM
532 Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine

hydrochloride (TCEP). Reactions were stopped by adding 2 × loading buffer and were then quenched at 75°C for 5 min. Samples were analyzed on a 20% urea denaturing polyacrylamide gel with TBE buffer. Cleavage products were visualized by toluidine blue staining.

RNA cleavage products phosphorylation assays

10 μM of unlabeled ITS2 RNA was incubated at 37°C for 1.5 h with 10 μM of Las1-Grc3 complex proteins in cleavage buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP). 1 mM ATP was added into each reaction system at 37°C for 30 min. Reactions were stopped by adding 2 × loading buffer and were then quenched at 75°C for 5 min. Samples were analyzed on a 20% urea denaturing polyacrylamide gel with TBE buffer. Cleavage products were visualized by toluidine blue staining.

GST pull-down assays

Pull-down experiments were carried out using GST fusion proteins to analyze the association between Las1 and Grc3. 0.2 mg purified GST-ScLas1 protein were incubated with 0.4 mg purified ScGrc3 protein in binding buffer containing 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 2 mM DTT. 80 μl GST affinity resin was added into each reaction system at 4°C for 60 min. The resin was washed with 1 ml of binding buffer. After washing five times, the binding samples were eluted with elution buffer containing 20 mM Tris, pH 7.5, 20 mM GSH, 500 mM NaCl, and 2 mM DTT. The elution samples were then monitored using SDS-PAGE (polyacrylamide gel electrophoresis) and visualized by Coomassie blue staining. The assays were quantified by band densitometry. The experiment was repeated three times.

Electrophoretic mobility shift assays

Electrophoretic mobility shift assays (EMSA) were performed with a series of Las1-Grc3 complex dilutions from 20 μM to 2 μM and a 81-nt ITS2 RNA. the

ITS2 RNA was synthesized by in vitro transcription. Proteins were incubated with ITS2 RNA in a binding buffer containing 20 mM Tris-HCl, pH 7.5, 300 mM NaCl for 30 min at 4°C. After reaction, the binding samples were then resolved on 5% native acrylamide gels in Tris-Glycine (0.5X TBE) buffer pH 8.5 under an electric field of 100 volts for 40 min at 4°C. Gels were imaged by using a ChemiDoc XRS+ (Bio-rad).

RNA sequencing

Enzyme-digested products from the ITS2 cleavage assay were isolated by dialysis from denaturing polyacrylamide gel. T4 PNK was used to phosphorylate the 5' terminus of RNA products. After the above treatment, RNA samples were linked with the adaptor RNA by T4 RNA ligase-1. RNA samples were then treated for reverse transcription and PCR amplification. The PCR amplification products were cloned into pET28a vector, then sequenced.

574

Data availability

The atomic coordinates included in this study have been deposited in the Protein Data Bank (PDB) with the following accession codes: 7Y16, 7Y17, and 7Y18. Cryo-EM maps of the ScLas1-Grc3 complex and CjLas1-Grc3 complex in this study have been deposited in the wwPDB OneDep System under EMD accession code EMD-33733 and EMD-33735.

Acknowledgements

We are grateful to the staff of the BL-17U1, BL-18U1 and BL-19U1 beamlines at the National Center for Protein Sciences Shanghai (NCPSS) at Shanghai Synchrotron Radiation Facility (SSRF).

Author contributions

J.C., H.C., X.L., and R.H. expressed and purified the proteins and grew crystals. J.C., H.C., and L.L. collected X-ray diffraction data. S.L., K.Z., and L.L. solved the structures. X.L., H.C., R.H., and J.C. carried out all of the cloning and performed the biochemical assays. L.L. prepared the figures; L.L. wrote the manuscript and supervised all of the research.

Funding

National Natural Science Foundation of China [32171286].

- Liang Liu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Competing interests

The authors declare no competing interests.

References

- Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B., . . . Zhang, F. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science*, 353(6299), aaf5573. doi:10.1126/science.aaf5573
- Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., . . . Terwilliger, T. C. (2002). PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr D Biol Crystallogr*, 58(Pt 11), 1948-1954. doi:10.1107/s09074444902016657
- Anger, A. M., Armache, J. P., Berninghausen, O., Habeck, M., Subklewe, M., Wilson, D. N., &

609 Beckmann, R. (2013). Structures of the human and Drosophila 80S ribosome. *Nature*,
610 497(7447), 80-85. doi:10.1038/nature12104

611 Castle, C. D., Cassimere, E. K., & Denicourt, C. (2012). LAS1L interacts with the mammalian
612 Rix1 complex to regulate ribosome biogenesis. *Mol Biol Cell*, 23(4), 716-728.
613 doi:10.1091/mbc.E11-06-0530

614 Castle, C. D., Cassimere, E. K., Lee, J., & Denicourt, C. (2010). Las1L is a nucleolar protein
615 required for cell proliferation and ribosome biogenesis. *Mol Cell Biol*, 30(18),
616 4404-4414. doi:10.1128/MCB.00358-10

617 Castle, C. D., Sardana, R., Dandekar, V., Borgianini, V., Johnson, A. W., & Denicourt, C.
618 (2013). Las1 interacts with Grc3 polynucleotide kinase and is required for ribosome
619 synthesis in *Saccharomyces cerevisiae*. *Nucleic Acids Res*, 41(2), 1135-1150.
620 doi:10.1093/nar/gks1086

621 Coleman, A. W. (2003). ITS2 is a double-edged tool for eukaryote evolutionary comparisons.
622 *Trends Genet*, 19(7), 370-375. doi:10.1016/S0168-9525(03)00118-5

623 Cote, C. A., Greer, C. L., & Peculis, B. A. (2002). Dynamic conformational model for the role of
624 ITS2 in pre-rRNA processing in yeast. *RNA*, 8(6), 786-797.
625 doi:10.1017/s1355838202023063

626 Credle, J. J., Finer-Moore, J. S., Papa, F. R., Stroud, R. M., & Walter, P. (2005). On the
627 mechanism of sensing unfolded protein in the endoplasmic reticulum. *Proc Natl Acad*
628 *Sci U S A*, 102(52), 18773-18784. doi:10.1073/pnas.0509487102

629 Doseff, A. I., & Arndt, K. T. (1995). LAS1 is an essential nuclear protein involved in cell
630 morphogenesis and cell surface growth. *Genetics*, 141(3), 857-871.

631 doi:10.1093/genetics/141.3.857

632 Doudna, J. A., & Rath, V. L. (2002). Structure and function of the eukaryotic ribosome: the next

633 frontier. *Cell*, 109(2), 153-156. doi:10.1016/s0092-8674(02)00725-0

634 Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010). Features and development of

635 Coot. *Acta Crystallogr D Biol Crystallogr*, 66(Pt 4), 486-501.

636 doi:10.1107/S0907444910007493

637 Fernandez-Pevida, A., Kressler, D., & de la Cruz, J. (2015). Processing of preribosomal RNA

638 in *Saccharomyces cerevisiae*. *Wiley Interdiscip Rev RNA*, 6(2), 191-209.

639 doi:10.1002/wrna.1267

640 Fromm, L., Falk, S., Flemming, D., Schuller, J. M., Thoms, M., Conti, E., & Hurt, E. (2017).

641 Reconstitution of the complete pathway of ITS2 processing at the pre-ribosome. *Nat*

642 *Commun*, 8(1), 1787. doi:10.1038/s41467-017-01786-9

643 Gasse, L., Flemming, D., & Hurt, E. (2015). Coordinated Ribosomal ITS2 RNA Processing by

644 the Las1 Complex Integrating Endonuclease, Polynucleotide Kinase, and

645 Exonuclease Activities. *Mol Cell*, 60(5), 808-815. doi:10.1016/j.molcel.2015.10.021

646 Gordon, J., Pillon, M. C., & Stanley, R. E. (2019). Nol9 Is a Spatial Regulator for the Human

647 ITS2 Pre-rRNA Endonuclease-Kinase Complex. *J Mol Biol*, 431(19), 3771-3786.

648 doi:10.1016/j.jmb.2019.07.007

649 Granneman, S., Petfalski, E., & Tollervey, D. (2011). A cluster of ribosome synthesis factors

650 regulate pre-rRNA folding and 5.8S rRNA maturation by the Rat1 exonuclease. *EMBO*

651 *J*, 30(19), 4006-4019. doi:10.1038/emboj.2011.256

652 Holm, L., & Rosenstrom, P. (2010). Dali server: conservation mapping in 3D. *Nucleic Acids*

653 *Res*, 38(Web Server issue), W545-549. doi:10.1093/nar/gkq366

654 Huang, H., Zeqiraj, E., Dong, B., Jha, B. K., Duffy, N. M., Orlicky, S., . . . Sicheri, F. (2014).

655 Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for

656 interferon-induced antiviral activity. *Mol Cell*, 53(2), 221-234.

657 doi:10.1016/j.molcel.2013.12.025

658 Khatteer, H., Myasnikov, A. G., Natchiar, S. K., & Klaholz, B. P. (2015). Structure of the human

659 80S ribosome. *Nature*, 520(7549), 640-645. doi:10.1038/nature14427

660 Knott, G. J., East-Seletsky, A., Cofsky, J. C., Holton, J. M., Charles, E., O'Connell, M. R., &

661 Doudna, J. A. (2017). Guide-bound structures of an RNA-targeting A-cleaving

662 CRISPR-Cas13a enzyme. *Nat Struct Mol Biol*, 24(10), 825-833.

663 doi:10.1038/nsmb.3466

664 Korennykh, A. V., Egea, P. F., Korostelev, A. A., Finer-Moore, J., Zhang, C., Shokat, K. M., . . .

665 Walter, P. (2009). The unfolded protein response signals through high-order assembly

666 of Ire1. *Nature*, 457(7230), 687-693. doi:10.1038/nature07661

667 Lafontaine, D. L. (2015). Noncoding RNAs in eukaryotic ribosome biogenesis and function.

668 *Nat Struct Mol Biol*, 22(1), 11-19. doi:10.1038/nsmb.2939

669 Lee, K. P., Dey, M., Neculai, D., Cao, C., Dever, T. E., & Sicheri, F. (2008). Structure of the

670 dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional

671 RNA splicing. *Cell*, 132(1), 89-100. doi:10.1016/j.cell.2007.10.057

672 Liu, L., Li, X., Ma, J., Li, Z., You, L., Wang, J., . . . Wang, Y. (2017). The Molecular Architecture

673 for RNA-Guided RNA Cleavage by Cas13a. *Cell*, 170(4), 714-726 e710.

674 doi:10.1016/j.cell.2017.06.050

675 Liu, L., Li, X., Wang, J., Wang, M., Chen, P., Yin, M., . . . Wang, Y. (2017). Two Distant
676 Catalytic Sites Are Responsible for C2c2 RNase Activities. *Cell*, 168(1-2), 121-134
677 e112. doi:10.1016/j.cell.2016.12.031

678 Naka, K., Koga, M., Yonesaki, T., & Otsuka, Y. (2014). RNase HI stimulates the activity of
679 RnIA toxin in Escherichia coli. *Mol Microbiol*, 91(3), 596-605. doi:10.1111/mmi.12479

680 Niewoehner, O., Garcia-Doval, C., Rostol, J. T., Berk, C., Schwede, F., Bigler, L., . . . Jinek, M.
681 (2017). Type III CRISPR-Cas systems produce cyclic oligoadenylate second
682 messengers. *Nature*, 548(7669), 543-548. doi:10.1038/nature23467

683 Otwinowski, Z., & Minor, W. (1997). Processing of X-ray diffraction data collected in oscillation
684 mode. *Methods Enzymol*, 276, 307-326.

685 Pillon, M. C., Goslen, K. H., Gordon, J., Wells, M. L., Williams, J. G., & Stanley, R. E. (2020). It
686 takes two (Las1 HEPN endoribonuclease domains) to cut RNA correctly. *J Biol Chem*,
687 295(18), 5857-5870. doi:10.1074/jbc.RA119.011193

688 Pillon, M. C., Hsu, A. L., Krahn, J. M., Williams, J. G., Goslen, K. H., Sobhany, M., . . . Stanley,
689 R. E. (2019). Cryo-EM reveals active site coordination within a multienzyme pre-rRNA
690 processing complex. *Nat Struct Mol Biol*, 26(9), 830-839.
691 doi:10.1038/s41594-019-0289-8

692 Pillon, M. C., Sobhany, M., Borgnia, M. J., Williams, J. G., & Stanley, R. E. (2017). Grc3
693 programs the essential endoribonuclease Las1 for specific RNA cleavage. *Proc Natl*
694 *Acad Sci U S A*, 114(28), E5530-E5538. doi:10.1073/pnas.1703133114

695 Pillon, M. C., & Stanley, R. E. (2018). Nuclease integrated kinase super assemblies (NiKs) and
696 their role in RNA processing. *Curr Genet*, 64(1), 183-190.

doi:10.1007/s00294-017-0749-9

Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. J. N. m. (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *14*(3), 290-296.

Rhou, A., & Grigorieff, N. J. J. o. s. b. (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *192*(2), 216-221.

Scheres, S. H. J. J. o. s. b. (2012). RELION: implementation of a Bayesian approach to cryo-EM structure determination. *180*(3), 519-530.

Schillewaert, S., Wacheul, L., Lhomme, F., & Lafontaine, D. L. (2012). The evolutionarily conserved protein Las1 is required for pre-rRNA processing at both ends of ITS2. *Mol Cell Biol*, *32*(2), 430-444. doi:10.1128/MCB.06019-11

Tang, G., Peng, L., Baldwin, P. R., Mann, D. S., Jiang, W., Rees, I., & Ludtke, S. J. J. J. o. s. b. (2007). EMAN2: an extensible image processing suite for electron microscopy. *157*(1), 38-46.

Tomecki, R., Sikorski, P. J., & Zakrzewska-Placzek, M. (2017). Comparison of preribosomal RNA processing pathways in yeast, plant and human cells - focus on coordinated action of endo- and exoribonucleases. *FEBS Lett*, *591*(13), 1801-1850. doi:10.1002/1873-3468.12682

Wang, Y., Li, Y., Toth, J. I., Petroski, M. D., Zhang, Z., & Zhao, J. C. (2014). N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells. *Nat Cell Biol*, *16*(2), 191-198. doi:10.1038/ncb2902

Wilson, D. N., & Doudna Cate, J. H. (2012). The structure and function of the eukaryotic ribosome. *Cold Spring Harb Perspect Biol*, *4*(5). doi:10.1101/cshperspect.a011536

719 Woolford, J. L., Jr., & Baserga, S. J. (2013). Ribosome biogenesis in the yeast
720 *Saccharomyces cerevisiae*. *Genetics*, *195*(3), 643-681.
721 doi:10.1534/genetics.113.153197

722 Wu, S., Tutuncuoglu, B., Yan, K., Brown, H., Zhang, Y., Tan, D., . . . Gao, N. (2016). Diverse
723 roles of assembly factors revealed by structures of late nuclear pre-60S ribosomes.
724 *Nature*, *534*(7605), 133-137. doi:10.1038/nature17942

725 Xiang, S., Cooper-Morgan, A., Jiao, X., Kiledjian, M., Manley, J. L., & Tong, L. (2009).
726 Structure and function of the 5'→3' exoribonuclease Rat1 and its activating partner
727 Rai1. *Nature*, *458*(7239), 784-788. doi:10.1038/nature07731

728 Zhang, C., Konermann, S., Brideau, N. J., Lotfy, P., Wu, X., Novick, S. J., . . . Lyumkis, D.
729 (2018). Structural Basis for the RNA-Guided Ribonuclease Activity of
730 CRISPR-Cas13d. *Cell*, *175*(1), 212-223 e217. doi:10.1016/j.cell.2018.09.001

731 Zheng, S. Q., Palovcak, E., Armache, J.-P., Verba, K. A., Cheng, Y., & Agard, D. A. J. N. m.
732 (2017). MotionCor2: anisotropic correction of beam-induced motion for improved
733 cryo-electron microscopy. *14*(4), 331-332.

734 Figure Legends

736 **Figure 1. ScLas1 specifically cleaves ITS2 at C2 and C2' sites. (A)** 33-nt
737 ITS2 RNA with 5'-Cy5 and 3'-Cy3 labels. **(B)** *In vitro* RNA cleavage assay
738 using 5'-Cy5 and 3'-Cy3 labeled 33-nt RNA. **(C)** *In vitro* RNA cleavage assay of
739 unlabeled 33-nt RNA. **(D)** 81-nt ITS2 RNA. **(E)** *In vitro* RNA cleavage assay of
740 unlabeled 81-nt RNA. **(F)** RNA-sequencing traces from ScLas1-cleaved ITS2

741 products P2 and P4. **(G)** RNA phosphorylation assay with ScLas1-Grc3
742 complex. **(H)** RNA degradation assay with ScRat1-Rai1 complex. **(I)** The ITS2
743 pre-rRNA processing pathway.

744 The following figure supplements are available for Figure 1:

745 **Figure 1 – Figure Supplement 1.** CjGrc3-activated CjLas1-catalytic ITS2
746 pre-rRNA cleavage.

747 **Figure 1 – Figure Supplement 2.** ScGrc3 has no ITS2 pre-rRNA cleavage
748 activity.

749 **Figure 1 – Figure Supplement 3.** Catalytic residues of Las1 HEPN domain
750 are necessary for ITS2 pre-rRNA cleavage.

751 **Figure 1 – Figure Supplement 4.** Characterization of the metal independence
752 of ITS2 pre-rRNA cleavage.

753

754 **Figure 2. Overall structure of ScLas1-Grc3 complex. (A)** Domain
755 organization of ScLas1 and ScGrc3. **(B)** Ribbon representations of
756 ScLas1-Grc3 complex. Color-coding used for Las1 and Grc3 is identical to that
757 used in Fig. 2a. **(C)** Surface representations of ScLas1-Grc3 complex.
758 Color-coding used for Las1 and Grc3 is identical to that used in Figure 2A.

759 The following figure supplement is available for Figure 2:

760 **Figure 2 – Figure Supplement 1. Single-particle cryo-EM analysis of the**
761 **ScLas1-Grc3 complex. (A)** Representative motion-corrected cryo-EM
762 micrograph. **(B)** Reference-free 2D class averages. **(C)** Workflow of the data
763 processing. **(D)** Euler angle distribution of the particle images. **(E)** Gold
764 standard FSC plot for the 3D reconstruction with full particle set, calculated in
765 cryoSPARC. **(F)** Resolution map for the final 3D reconstruction.

766

767 **Figure 3. Overall structure of CjLas1-Grc3 complex. (A)** Domain
768 organization of CjLas1 and CjGrc3. **(B)** Ribbon representations of CjLas1-Grc3

769 complex. Color-coding used for Las1 and Grc3 is identical to that used in Fig.
770 3a. **(C)** Surface representations of CjLas1-Grc3 complex. Color-coding used
771 for Las1 and Grc3 is identical to that used in Figure 3A.

772 The following figure supplements are available for Figure 3:

773 **Figure 3 – Figure Supplement 1. Single-particle cryo-EM analysis of the**
774 **CjLas1-Grc3 complex. (A)** Representative motion-corrected cryo-EM
775 micrograph. **(B)** Reference-free 2D class averages. **(C)** Workflow of the data
776 processing. **(D)** Euler angle distribution of the particle images. **(E)** Gold
777 standard FSC plot for the 3D reconstruction with full particle set, calculated in
778 cryoSPARC. **(F)** Resolution map for the final 3D reconstruction.

779 **Figure 3 – Figure Supplement 2. Comparison of cryo-EM and crystal**
780 **structures of Las1-Grc3 complexes. (A)** Superposition of the ScLas1-Grc3
781 complex crystal structure with the cryo-EM structure. Color-coding used for
782 ScLas1 and ScGrc3 in crystal structure is identical to that used in Fig. 2a.
783 ScLas1 and ScGrc3 in cryo-EM structure are colored in gray. **(B)**
784 Superposition of the CjLas1-Grc3 complex crystal structure with the cryo-EM
785 structure. Color-coding used for CjLas1 and CjGrc3 in crystal structure is
786 identical to that used in Fig. 3a. CjLas1 and CjGrc3 in cryo-EM structure are
787 colored in gray.

788 **Figure 3 – Figure Supplement 3. Sequence alignment of Las1 proteins.**
789 The ScLas1 protein was aligned with its respective homologs. Alignment was
790 performed using the MUSCLE program. The secondary structures of ScLas1
791 and CjLas1 are shown above and below the sequences, respectively.
792 Conserved residues are highlighted in yellow, and invariant residues are
793 highlighted in red. Catalytic residues in Las1 HEPN domain are marked in
794 violet triangles. The figure was prepared using ESPript3.

795

796 **Figure 4. The CC domain contributes to ITS2 RNA binding and cleavage.**

797 **(A)** Structural comparison between ScLas1-Grc3 complex and CjLas1-Grc3
 798 complex. Color-coding used for ScLas1 and ScGrc3 is identical to that used in
 799 Fig. 2a. The CC domain of CjLas1 is colored in salmon, other domains of
 800 CjLas1 and all domains of CjGrc3 are colored in gray. **(B)** Structures of CjLas1
 801 CC domain (in salmon) and ScLas1 CC domain (in lightmagenta). **(C)** *In vitro*
 802 RNA cleavage assay using indicated truncations of ScLas1. **(D)**
 803 Electrophoretic mobility shift assay using indicated truncations of ScLas1.

804

805 **Figure 5. ScGrc3 GCT mediates the ITS2 cleavage activity of ScLas1.** **(A)**
 806 ScGrc3 GCT binds at an active channel of ScLas1 HEPN dimer. Two HEPN
 807 domains of Las1 are colored in pink and violet, respectively. GCTs of Grc3 are
 808 colored in teal. The catalytic site is highlighted in yellow. HEPN domains are
 809 shown as surfaces, while GCTs are shown as sticks. **(B)** Detailed interactions
 810 between ScGrc3 GCT and ScLas1 HEPN domain. **(C)** Sequence alignments
 811 of Grc3 GCTs. Identical residues are highlighted in red. Basically constant
 812 residuals are shaded in blue. Conserved residues are shaded in orange. **(D)** *In*
 813 *vitro* enzymatic assay of mutations of ScGrc3 residues Glu614, His615 and
 814 Trp617. **(E)** GST pull-down experiment assaying the ability of ScGrc3 mutants
 815 to interact with ScLas1. **(F)** *In vitro* enzymatic assay of alanine mutations of
 816 ScGrc3 C-terminal residues.

817 The following figure supplement is available for Figure 5:

818 **Figure 5 – Figure Supplement 1.** *In vitro* enzymatic assay of alanine
 819 mutations of conserved CjGrc3 residues Trp618, Arg601, Arg606 and Arg607.

820

821 **Figure 6. Las1 LCT drives Las1-Grc3 cross talk.** **(A)** ScLas1 LCT binds to
 822 the CTD domain of ScGrc3. ScGrc3 is shown as surface, ScLas1 LCT is
 823 shown as stick. **(B)** Detailed interactions between C-terminal residues of
 824 ScLas1 LCT and ScGrc3 CTD domain. **(C)** Detailed interactions between

825 N-terminal residues of ScLas1 LCT and ScGrc3 CTD domain.

826 The following figure supplements are available for Figure 6:

827 **Figure 6 – Figure Supplement 1.** Denaturing gel showing the ITS2 pre-RNA
828 cleavage by mutation or deletion of the interacting residues of ScLas1 LCT.

829 **Figure 6 – Figure Supplement 2.** GST pull-down experiment assaying the
830 Grc3 binding ability by mutation or deletion of the interacting residues of
831 ScLas1 LCT.

832

833 **Figure 7. Activation mechanism of Las1 by Grc3. (A)** Crystal structure of
834 CjLas1 HEPN domain. **(B)** The HEPN3 molecule (in slate) and its
835 symmetry-related molecule (in bluewhite) in Las1 HEPN domain structure. **(C)**
836 The HEPN1 (in pink) and HEPN2 (in violet) molecules in Las1 HEPN domain
837 structure. **(D)** Structural comparison of HEPN dimers between CjLas1-Grc3
838 complex (Las1A HEPN in pink, Las1B HEPN in violet) and CjLas1 HEPN
839 domain (in gray). Inset: a magnified view of the comparison of the catalytic site
840 in the two structures.

841 The following figure supplements are available for Figure 7:

842 **Figure 7 – Figure Supplement 1.** Structural superposition of HEPN3 (in slate)
843 and its symmetry-related molecule (in bluewhite) with the HEPN1(in
844 pink)-HEPN2 (in violet) dimer.

845 **Figure 7 – Figure Supplement 2.** Structural comparison of HEPN dimers
846 between ScLas1-Grc3 complex (Las1A HEPN in pink, Las1B HEPN in violet)
847 and CjLas1 HEPN domain (in gray). Inset: a magnified view of the comparison
848 of the catalytic site in the two structures.

849

850 **Figure 8. Model for Grc3-mediated Las1-catalyzed ITS2 pre-rRNA**
851 **processing.** Prior to assembly with Grc3, Las1 shows weak processing
852 activity for ITS2 precursor RNA. When combined with Grc3 to form a tetramer

853 complex, Las1 shows high processing activity for ITS2 precursor RNA. Las1
854 specifically cleaves ITS2 at C2 and C2' sites to generate 5'-OH terminus
855 products. The 5'-OH terminus products are further phosphorylated by Grc3
856 when in the presence of ATP.

857 The following figure supplement is available for Figure 8:

858 **Figure 8 – Figure Supplement 1. Comparison of Las1-Grc3, Ire1 and**
859 **RNase L.** Comparison of structural assembly, activation and substrate
860 recognition mechanisms of Las1-Grc3, Ire1 and RNase L. Two HEPN domains
861 in Las1, Ire1 and RNase L are colored in pink and violet, respectively. Two
862 PNK domains in Grc3, two Kinase domains in Ire1, and two Pseudo-Kinase
863 domains in RNase L, are colored in cyan and greencyan, respectively. The
864 catalytic site is highlighted with a yellow box.
865

866 **Table 1. Crystallographic data collection and refinement statistics.**

	ScLas1-Grc3	CjLas1-Grc3	CjLas1
Data collection*			
Space group	C2	C222 ₁	P2 ₁ 2 ₁ 2 ₁
Cell dimensions			
<i>a</i> , <i>b</i> , <i>c</i> (Å)	233.6, 116.1, 159.3	152.6, 240.0, 237.0	51.5, 59.0, 158.7
α , β , γ (°)	90.0, 96.4, 90.0	90.0, 90.0, 90.0	90.0, 90.0, 90.0
Resolution (Å)	50.00-3.50 (3.56-3.50)	50.00-3.23 (3.29-3.23)	50.00-1.80 (1.83-1.80)
<i>R</i> _{merge}	0.298 (0.980)	0.344 (0.958)	0.103 (0.929)
<i>I</i> / σ	4.8 (1.1)	4.3 (1.6)	22.0 (2.5)
Completeness (%)	98.8 (96.5)	99.9 (99.9)	97.7 (95.8)
Redundancy	4.5 (3.5)	7.5 (6.4)	10.1 (9.5)
Refinement			
Resolution (Å)	3.69	3.39	1.80
No. reflections	36,773	41,321	44,296
<i>R</i> _{work} / <i>R</i> _{free}	0.2798/0.3151	0.3041/0.3281	0.2120/0.2334
No. atoms			
protein	22,873	18,763	3,657
Water	180	386	212
<i>B</i> -factors (Å ²)			
Protein	95.5	125.6	23.3
Water	33.2	55.9	28.5
R.m.s. deviations			
Bond length (Å)	0.008	0.011	0.015
Bond angles (°)	1.516	1.785	1.500
Ramachandran plot			
Favored region	94.96	95.72	97.98
Allowed region	4.86	4.28	2.02
Outlier region	0.18	0.00	0.00

867 * Highest resolution shell is shown in parentheses.

868

869 **Table 2. Cryo-EM data collection and processing.**

	ScLas1-Grc3	CjLas1-Grc3
Data collection and processing		
Microscope	Titan Krios	Titan Krios
Voltage (kV)	300	300
Camera	Gatan K3	Gatan K3
Magnification	105,000x	105,000x
Pixel size (Å)	0.82	0.82
Total exposure (e-/Å ²)	50	50
Exposure time (s)	3	3
Number of frames per exposure	30	30
Energy filter slit width (keV)	20	20
Data collection software	EPU	EPU
Defocus range (µm)	-1.3 - -2.7	-1.2 - -3
Number of micrographs	2,520	8,616
Number of initial particles	525,213	2,215,555
Symmetry	C2	C2
Number of final particles	264,341	523,843
Resolution (0.143 gold standard FSC, Å)	3.07	3.39
Local resolution range (Å)	2.8-4.8	2.8-4.8

870




Figure 1




Figure 1—figure supplement 1




Figure 1—figure supplement 2




Figure 1—figure supplement 3




Figure 1—figure supplement 4




Figure 2




Figure 2-figure supplement 1




Figure 3




Figure 3—figure supplement 1





Figure 3—figure supplement 2

HEPN

β1

ScLas1 1 .MIPPRIVPW^{RDFA}ELEELKLW^{FYPK}.....SKGTIEDKRQ^{RAV}Q^RVQSYRLKGSQYLP^{HVV}D^{STA}QIT
ScLas1 1 .MVQYIFT^{PWRNRA}ELLAVRAQ^{FYP}PEHTSKTHLKKHHQSTFQDDEHIRSEKQ^{KAVAR}VSMWMQ^{RGG}..CP^{HMV}E^{STA}LLV
CjLas1 1 MNSHPRLT^{PWKSSD}EVVYLKGL^{FFFP}ADREQI.....SRDELYRQY^{EAL}SLVEMYSSRTR..VS^{HIL}Q^{STA}HLF
CjLas1 η1 α1 α2 α3

ScLas1 α4 α5 α6 α7
ScLas1 64 CAV^{LLD}EKEACLG^{VHQDSIP}IFLSYV^{MALIRFVN}G^LLDP^TQ^{QS}QFAIP^LHTL^{AAK}I^GLP^{SWFVD}L^{RHWG}T^{HE}RD^{LPS}G^LEM
CtLas1 78 AA^{ILSD}E^{AQG}..SGAAGGYA^{VRAA}YSA^{AFSRFVT}G^LLDS^HQ^{DK}Q^{RKQSMYDV}AKA^{VGLP}AA^{FVEL}R^{RHQA}T^{HE}Q^{LPS}I^{TR}
CjLas1 68 SA^{LMML}E^{SFE}..GGLDDT..V^{RLTASMTII}R^{FVN}G^LLDP^NQ^{QS}QFAIP^LHLL^{AKK}I^DLP^{SLFVE}F^{RHSA}T^{HD}A^{LPS}I^{EM}
CjLas1 α4 α5 α6 α7

ScLas1 α8 α9 η1 α10 α11
ScLas1 144 LRWAANE^{ALS}W^{LYDH}Y^{WN}DEELED^{DR}D^{DDDD}D^{DDDD}TG^{YGYRRNDKL}E^{KYME}SLTK^{TL}DKW^{KRLRNEF}L^{EYK}WV^{WENAND}SL
CtLas1 155 LRSAARRA^{LEW}I^{WWY}Y^{WK}GLGP^{VD}MD^VQ^{RGV}N^{GKG}VAG^VGD^{TSESE}E^{KDV}GEE.....
CjLas1 143 CKTCVDR^{AID}W^{VVDH}Y^{WD}DG..VLSIV^EPQ^{VE}T^{DDL}.....E^{SLIK}ELK^{DL}FK^{QYRR}IR^{RQ}NI^TKL^{YK}FG^DSTP..
CjLas1 α6 α7

ScLas1 α12 α13 α14 η2 α15
ScLas1 224 ITSSNFS^GDNLVNYDAEK^{RKSS}HASS^{SETMIRE}NLRQ^{WQEL}W^{KLSI}YHN^VL^EKFF^NNY^DP^LLL^{KVL}.MLN^{LNN}FD^WKVI
CtLas1 207GGDAAARCREGV...VRLLES^DVRV^{GGE}AIN^{GP}GKEEL.....L^AEFG...E^{AL}VL^TTL^DAA^{AGN}TRD^VGV
CjLas1 210E^GK^{EY}WT^{CI}AG^{IK}DHAD^{MANFYN}MIER^{IV}SN^{KL}KWEH.....L^RAL^F...E^PM^MNH^{FI}.HL^KGW^DFP^LGLI
CjLas1 α8 α9 α10

ScLas1 α16 α17 α18 α19 α20 α21 α22
ScLas1 303 EWVARNYRTQ^QDDSNIT^{IL}LKR^{KFNA}WKEL^QKRL^{LD}VI^INN^LN^NK^NF^KN..K^{WQ}NWE^KLIDENAS^{YL}IL^YFC^QSML^AK^{TE}
CtLas1 268DVE^KL^IKEEL^{KKG}.....WEE^IKRLA^QEKED^SGDD^QTED.....
CjLas1 273DSML^{SKNYE}YS^KF..RGID^DTERAY^LN^DQ^EFK^{CAQ}KWIR^W.....
CjLas1 α11 α12

ScLas1 η3 α23 α24
ScLas1 381 T^EKIT^GN^{SWRN}KKRR^{KQID}STVEIEAK^{LK}.ENI^DN^LSLRFNEGEIK^{LYDF}IPAEK^{DS}VPL^KKEV^{SP}ALK^{AD}T.....
CtLas1 288 L^ENGKGNR.....DVE^KL^IKEEL^{KKG}.....WEE^IKRLA^QEKED^SGDD^QTED.....
CjLas1 313 I^EQI..^DRYDD^{VL}VSKMID^TLGKT^{NH}ELN^VELL^EK^LQSR^FSAD.....PVI^KDKI^QAK^LT^LI^QRLSTD^TKTKRM^{NN}L
CjLas1 α13 α14 α15

LCT

β2

ScLas1
ScLas1 452 N^DI^LLG^DLAS^LKQ^RMSS^FGT^VGK^KN^KQ^{EEN}RAT^PVKN^WSR^VQ^NW^KP^KP^FGV^L
CtLas1 329 E^DV^DME^AEEED^KKEQ^QSGW^VLYDE^KE^E.....W^VP^KP^IGV^I
CjLas1 383 E^DI^MSD^LES^LKKRA^KVT^PTL^HIK^SF^E.....SHPN^WT^PK^PF^{GV}I

Figure 3—figure supplement 3




Figure 4




Figure 5





Figure 5—figure supplement 1




Figure 6




Figure 6—figure supplement 1




Figure 6—figure supplement 2




Figure 7




Figure 7—figure supplement 1




Figure 7—figure supplement 2





Figure 8


Las1-Grc3



RNA cleavage

pre-rRNA Motif: UAG, UGC


Ire1



RNA cleavage

mRNA Motif: AGC, CGA, UGC

RNase L



RNA cleavage

mRNA Motif: UUN, UAN

Figure 8—figure supplement 1